quinoxalines has been researched along with cotinine in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brunnemann, KD; Hornby, AP; Stich, HF | 1 |
| Burstein, AH; Clark, DJ; Faessel, HM; Gibbs, MA; Rohrbacher, K; Stolar, M | 1 |
| Benowitz, NL | 1 |
| Herman, AI; Mooney, M; Sofuoglu, M; Waters, AJ | 1 |
| Costa, E; Davis, JM; Guidotti, A; Lajtha, A; Maloku, E; Sershen, H; Smith, RC; Zhubi, A | 1 |
| Fagerström, K; Gilljam, H; Messig, M; Metcalfe, M; Tonstad, S | 1 |
| Dhanji, AR; Hajek, P; McRobbie, HJ; Myers, KE; Stapleton, J | 1 |
| Cohen, J; Cui, Q; Elston, D; McFarland, N; McIvor, A; Quan, C; Robinson, L; Smaill, F; Smieja, M; Thabane, L; Zeidler, J | 1 |
| Ansermot, N; Choong, E; Cornuz, J; Dobrinas, M; Eap, CB; Noetzli, M | 1 |
| Alvarez-Estrada, M; Brody, AL; Lotfipour, S; Mandelkern, M | 1 |
| Johnson, MW; McClure, EA; Stitzer, ML; Vandrey, RG | 1 |
| Ashare, RL; Blair, IA; Leone, F; Mesaros, AC; Strasser, AA; Tang, KZ | 1 |
| Abrishami, A; Chapman, KR; Chung, F; Friedman, Z; Selby, P; Wong, J; Yang, Y; Zaki, A | 1 |
1 review(s) available for quinoxalines and cotinine
| Article | Year |
|---|---|
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.
Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Asian; Benzazepines; Black or African American; Bupropion; Cotinine; Cues; Cytochrome P-450 CYP2A6; Drug Tolerance; Genetic Predisposition to Disease; Harm Reduction; Humans; Menthol; Mixed Function Oxygenases; Neuronal Plasticity; Nicotine; Nicotinic Agonists; Quinoxalines; Receptors, Nicotinic; Reinforcement, Psychology; Smoking; Smoking Cessation; Tobacco Use Disorder; United States; Varenicline; White People | 2008 |
8 trial(s) available for quinoxalines and cotinine
| Article | Year |
|---|---|
Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Benzazepines; Cotinine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Half-Life; Headache; Humans; Hypotension, Orthostatic; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Nicotine; Patient Dropouts; Quinoxalines; Receptors, Nicotinic; Smoking; Smoking Cessation; Smoking Prevention; Tablets; Varenicline; Vomiting | 2006 |
Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans.
Topics: Adult; Affect; Benzazepines; Blood Pressure; Cognition Disorders; Cotinine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Rate; Humans; Injections, Intravenous; Male; Middle Aged; Neuropsychological Tests; Nicotine; Nicotinic Agonists; Quinoxalines; Severity of Illness Index; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2009 |
Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial.
Topics: Adult; Benzazepines; Cotinine; Double-Blind Method; Female; Humans; Male; Nicotinic Agonists; Quinoxalines; Recurrence; Saliva; Tobacco Use Cessation; Tobacco Use Disorder; Tobacco, Smokeless; Treatment Outcome; Varenicline | 2010 |
Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates.
Topics: Adult; Benzazepines; Biomarkers; Cotinine; Double-Blind Method; Drug Administration Schedule; Female; Humans; London; Male; Middle Aged; Nicotinic Agonists; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome; Varenicline | 2011 |
Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study.
Topics: Adult; Affect; Benzazepines; Cotinine; Dreams; Female; Follow-Up Studies; HIV Seropositivity; Humans; Indicators and Reagents; Male; Middle Aged; Nausea; Nicotinic Agonists; Ontario; Pilot Projects; Prevalence; Quinoxalines; Sleep Initiation and Maintenance Disorders; Smoking; Smoking Cessation; Treatment Outcome; Varenicline | 2012 |
Effects of varenicline on abstinence and smoking reward following a programmed lapse.
Topics: Adult; Benzazepines; Cotinine; Female; Humans; Male; Middle Aged; Patient Compliance; Prospective Studies; Quinoxalines; Reward; Secondary Prevention; Smoking; Smoking Cessation; Smoking Prevention; Treatment Outcome; Varenicline | 2013 |
Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers.
Topics: Adult; alpha7 Nicotinic Acetylcholine Receptor; Behavior, Addictive; Benzazepines; Biomarkers; Cotinine; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Nicotine; Nicotinic Agonists; Patient Acceptance of Health Care; Pennsylvania; Quinoxalines; Receptors, Nicotinic; Smoking Cessation; Substance Withdrawal Syndrome; Time Factors; Varenicline; Young Adult | 2012 |
A perioperative smoking cessation intervention with varenicline: a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Benzazepines; Cotinine; Counseling; Double-Blind Method; Female; Health Promotion; Humans; Logistic Models; Male; Middle Aged; Perioperative Care; Postoperative Complications; Prospective Studies; Quinoxalines; Recurrence; Sample Size; Smoking; Smoking Cessation; Telephone; Tobacco Use Disorder; Treatment Outcome; Varenicline; Young Adult | 2012 |
4 other study(ies) available for quinoxalines and cotinine
| Article | Year |
|---|---|
Tobacco-specific nitrosamines in the saliva of Inuit snuff dippers in the Northwest Territories of Canada.
Topics: Canada; Cell Nucleus; Cotinine; Humans; Inuit; Male; Mouth Mucosa; Nicotiana; Nicotine; Nitrosamines; Plants, Toxic; Precancerous Conditions; Quinoxalines; Saliva; Tobacco Use Disorder; Tobacco, Smokeless | 1987 |
Varenicline treatment decreases DNMT1 mRNA expression in lymphocytes of schizophrenic patients who are cigarette smokers.
Topics: Benzazepines; Cotinine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Gene Expression; Humans; Nicotine; Nicotinic Agonists; Quinoxalines; RNA, Messenger; Schizophrenia; Smoking Cessation; Varenicline | 2010 |
Quantification of nicotine, cotinine, trans-3'-hydroxycotinine and varenicline in human plasma by a sensitive and specific UPLC-tandem mass-spectrometry procedure for a clinical study on smoking cessation.
Topics: Benzazepines; Chromatography, High Pressure Liquid; Cotinine; Drug Stability; Humans; Linear Models; Nicotine; Quinoxalines; Reproducibility of Results; Sensitivity and Specificity; Smoking Cessation; Tandem Mass Spectrometry; Varenicline | 2011 |
A single administration of low-dose varenicline saturates α4β2* nicotinic acetylcholine receptors in the human brain.
Topics: Adolescent; Adult; Aged; Benzazepines; Brain; Cotinine; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Quinoxalines; Radionuclide Imaging; Receptors, Nicotinic; Smoking; Varenicline | 2012 |